XMP1 Stock Chart & Stats
€2.47
-€0.04(-1.07%)
At close: 4:00 PM EDT
€2.47
-€0.04(-1.07%)
Day’s Range― - ―
52-Week Range€2.47 - €28.15
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€20.08M
Enterprise Value€21.60
Total Cash (Recent Filing)€8.59M
Total Debt (Recent Filing)€44.00K
Price to Earnings (P/E)―
Beta0.81
Next Earnings
Oct 15, 2026EPS Estimate
-0.76Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1033.41
Shares Outstanding7,589,625
10 Day Avg. Volume1
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)3.15
Price to Sales (P/S)2.42
P/FCF Ratio-0.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€45.84Price Target Upside1756.03% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-3.5
Revenue Forecast (FY)€5.39M
Bulls Say, Bears Say
Bulls Say
Low Leverage And Positive EquityThe company currently carries minimal debt and has positive equity, reducing interest burden and near-term creditor pressure. This provides more financial flexibility to direct available capital toward clinical development, although ongoing losses remain a constraint.
Strong Gross Margin ProfileA very high gross margin suggests the underlying economics of potential product revenue could be attractive if clinical programs reach approval and scale. The benefit is not yet realized because operating and research costs remain substantially above revenue.
Focused Targeted Radiotherapeutics PipelineConcentrating on targeted radiotherapeutics for CNS and other hard-to-treat cancers gives the company a defined development strategy and addresses areas of significant unmet need. Successful delivery of radiation while limiting healthy-tissue exposure could support future differentiation.
Bears Say
Sustained Cash Burn And Financing DependencePersistent operating and free-cash-flow deficits mean the company cannot currently fund development from operations. Continued clinical investment will likely require additional financing, creating dilution risk and dependence on external capital availability.
Small And Declining Revenue BaseThe shrinking, limited revenue base provides little internal support for research, development, or corporate overhead. Without a commercial product or sustained revenue growth, the company remains highly dependent on future clinical success and potential partnering.
Deep Losses And Ongoing Capital ErosionLarge recurring losses show that research and operating expenses materially exceed current revenue, keeping the business far from breakeven. The deeply negative return on equity indicates that shareholder capital is being consumed while development programs remain uncommercialized.
Cerenome News
XMP1 FAQ
What was Cerenome’s price range in the past 12 months?
Cerenome lowest stock price was €2.47 and its highest was €28.15 in the past 12 months.
What is Cerenome’s market cap?
Cerenome’s market cap is €20.08M.
When is Cerenome’s upcoming earnings report date?
Cerenome’s upcoming earnings report date is Oct 15, 2026 which is in 49 days.
How were Cerenome’s earnings last quarter?
Cerenome released its earnings results on Aug 14, 2026. The company reported -€1.124 earnings per share for the quarter, missing the consensus estimate of -€0.755 by -€0.369.
Is Cerenome overvalued?
According to Wall Street analysts Cerenome’s price is currently Undervalued.
Does Cerenome pay dividends?
Cerenome does not currently pay dividends.
What is Cerenome’s EPS estimate?
Cerenome’s EPS estimate is -0.76.
How many shares outstanding does Cerenome have?
Cerenome has 7,589,625 shares outstanding.
What happened to Cerenome’s price movement after its last earnings report?
Cerenome reported an EPS of -€1.124 in its last earnings report, missing expectations of -€0.755. Following the earnings report the stock price went down -5.145%.
Which hedge fund is a major shareholder of Cerenome?
Currently, no hedge funds are holding shares in DE:XMP1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cerenome
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The firm focuses on the development of chemotherapeutics and radio therapeutics for rare cancers that address unmet medical and market needs. Its products include Rhenium NanoLiposome and DocePLUS. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in Houston, TX.
XMP1 Stock 12 Month Forecast
Average Price Target
€45.84
▲(1756.03% Upside)
Karyopharm Therapeutics
―
Tvardi Therapeutics
―
Barinthus Biotherapeutics
―
Senti Biosciences
―
Acrivon Therapeutics, Inc.
―